BPC-157 research: what does the scientific literature actually show?

Research-use notice: this article is for legitimate laboratory and educational research only. It does not provide guidance for human use, administration, dosing or treatment.

BPC-157 is one of the most written-about research peptides and one of the least tested in people. It is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV, molecular weight about 1,419 Da) whose sequence was taken from a protein found in human gastric juice. A 2025 systematic review found 36 relevant studies: 35 in cells or animals and one retrospective chart review in people, with no clinical safety data at all. BPC-157 is not a licensed medicine anywhere, and this article sets out what the literature does and does not show.

What is BPC-157?

BPC stands for “body protection compound”. The peptide was described in the early 1990s by a group at the University of Zagreb led by Predrag Sikiric, who reported that a fragment of a gastric protein was stable in human gastric juice and protected the stomach lining in animal models. The synthetic 15-residue fragment they settled on is BPC-157, also called PL 14736 and, in one clinical programme, Bepecin.

The triple-proline motif in the middle of the sequence is often credited with its resistance to gastric acid and digestive enzymes, although the 2025 Pharmaceuticals review noted that the structural features that usually explain peptide stability, such as D-amino acids or terminal modifications, have not been reported for BPC-157. Our guide What are peptides? covers the basics of sequences and synthesis.

Where the evidence comes from

A PubMed search in May 2025 returned more than 190 papers mentioning BPC-157. Two things stand out before reading any of them.

First, the vast majority are animal studies, mostly in rats. Second, more than 80% of them list Predrag Sikiric or Sven Seiwerth of the Zagreb group as first or senior author. That is not unusual for a compound that one laboratory has worked on for thirty years, but it means the literature is narrower than the paper count suggests. Independent replication by other groups is limited, and Józwiak and colleagues, in their 2025 Pharmaceuticals reply to the Zagreb group, pointed out that experiments routinely use a single dose rather than a dose–response design.

Gastrointestinal models

This is the original research area and the largest body of work. Rat studies report protection against gastric ulcers induced by alcohol, NSAIDs and stress, faster healing of intestinal anastomoses and fistulas, and effects in experimental colitis and in colon ischaemia–reperfusion models. A 2017 World Journal of Gastroenterology paper from the Zagreb group is a representative example, reporting restored blood supply to ischaemic rat colon. These are model findings in animals.

Musculoskeletal models

The second major area, and the reason BPC-157 is discussed in sports medicine. The 2025 HSS Journal systematic review by Vasireddi and colleagues grouped the preclinical work as follows:

• Tendon: five rat Achilles tendon studies, including a 2003 transection study, reported improved tendon structure, biomechanics and motor function.
• Muscle: three rat transection and crush models reported improved muscle structure and function.
• Ligament: one medial collateral ligament model reported reduced post-injury valgus instability and contracture.
• Bone: one fracture non-union model found BPC-157 performed similarly to autologous bone marrow or bone graft in improving callus mineralisation.

All of these were in rodents. The review authors described the findings as promising but drawn from level IV and V evidence, and concluded that, given the limited high-quality clinical evidence, clinicians and athletes should exercise caution.

Other models

Smaller bodies of animal work cover the central nervous system, heart and smooth muscle, corneal healing and vascular injury. The common thread is the proposed mechanism: increased expression of growth factors such as VEGF, activation of the nitric oxide system and promotion of new blood vessel formation (angiogenesis). Whether that mechanism explains the results, and whether it would hold in people, remains hypothetical.

The human evidence, in full

As of October 2026 the published human record on BPC-157 is short enough to list completely.

That is the whole list: roughly 30 people across three uncontrolled pilot studies, two trials that exist only as abstracts, and a registered trial with no results. No randomised controlled trial has been published as a full paper. The 2025 systematic review found no clinical safety data, and a July 2026 Pharmacy Times article made the same point, counting three uncontrolled pilot studies with 30 participants between them.

The safety debate

Two claims circulate about BPC-157’s safety, and they pull in opposite directions.

The first is that animal studies report few side effects, which is true as far as it goes. The 2025 Pharmaceuticals review noted that only a few adverse effects have been reported following administration in the models studied.

The second is the one regulators act on. Because BPC-157 promotes angiogenesis and growth-factor signalling, the same review raised the hypothesis that long-term exposure could, in principle, support tumour growth. The Zagreb group published a detailed rebuttal in September 2025, arguing that BPC-157’s effects on angiogenesis and nitric oxide are modulatory rather than purely stimulatory. Józwiak and colleagues replied that the point remains unproven in either direction because basic pharmacodynamic and pharmacokinetic profiling has never been done. That exchange, in a single journal across three papers, is a fair summary of where the field is.

In September 2023 the US FDA placed BPC-157 in Category 2 of its 503A bulk-substance list, meaning it identified significant safety concerns, citing immunogenicity, peptide-related impurities and the lack of human safety data, and compounding pharmacies could not prepare it. In April 2026 the FDA removed BPC-157 and other peptides from Category 2 and referred them to its Pharmacy Compounding Advisory Committee. On 23 July 2026 that committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A bulks list for a proposed ulcerative colitis use, against the FDA’s own proposal not to include it. The vote is non-binding. As of October 2026 the FDA has not issued a final decision, and BPC-157 remains an unapproved drug in the US.

What this means for a research design

For laboratory work, the literature points to a few practical consequences.

• Use the rat models as the reference. Almost everything known about BPC-157’s behaviour was established in rodent tissue and wound models, so comparisons to published work are most meaningful in those systems.
• Include a dose range. Most published experiments used one or two fixed doses. A dose–response design adds information the literature currently lacks.
• Control for the salt. Synthetic BPC-157 is usually a TFA or acetate salt, and net peptide content varies by batch. Our article on TFA salt peptides explains why that affects cell and animal work.
• Confirm identity analytically. A 15-residue peptide can carry deletion and truncation variants that co-elute on HPLC. See peptide sequence impurities.

How to check a BPC-157 batch

Because BPC-157 is unlicensed, no regulator checks the quality of material sold as BPC-157. The batch laboratory report is the only evidence of what is in the vial. When reading one, check:

• The batch number matches the vial label.
• Identity is confirmed by mass spectrometry, with an observed mass consistent with about 1,419 Da for the free peptide.
• Purity is reported as an HPLC area percentage, and you read it as a separation result rather than a statement of content or sterility.
• Method, date and report reference are stated so the report can be verified with the laboratory.

Thistle publishes the laboratory report for the current BPC-157 batch on the product page, and any batch can be checked on our batch report lookup. For the method, see How to read a peptide COA and What does 99% purity actually mean?

Thistle supplies BPC-157 — 10mg Research Peptide at £27.99, and BPC-157 + TB-500 — 10mg Research Blend at £29.99, each with a batch laboratory report.

Is BPC-157 legal in the UK?

BPC-157 has no UK marketing authorisation as a medicine and is not a controlled drug under the Misuse of Drugs Act 1971. It is supplied as a research material for laboratory use. Presentation matters: in April 2026 the MHRA said that where clinics make medicinal claims for peptide injections, those products will be treated as medicines under the Human Medicines Regulations 2012. That is why Thistle describes what has been studied and makes no claims about treating, preventing or improving any condition.

In sport, BPC-157 has been named as an example under section S0 (non-approved substances) of the World Anti-Doping Agency’s Prohibited List since the 2022 list, and is named again on the 2026 list, which prohibits it at all times. Anti-doping bodies that apply the WADA code, including UK Anti-Doping, follow that list.

This section is general information, not legal advice.

Storage and handling

BPC-157 is supplied as a lyophilised powder in a sealed vial. Keep it sealed, dry and protected from heat and light, and follow the vial label and batch documentation. See our peptide storage guide.

BPC-157 FAQs

Is BPC-157 proven to work?

No. The evidence is almost entirely from rats and cell culture. The only human data are uncontrolled pilot studies and conference abstracts. No randomised controlled trial has been published.

Is BPC-157 safe?

Nobody knows. Animal studies report few adverse effects, but a 2025 systematic review found no clinical safety data, and the FDA flagged significant safety concerns in 2023 and in 2026 still proposed against allowing it to be compounded. BPC-157 is not for human use.

Why is BPC-157 called a “healing peptide”?

Because rat wound, tendon and gut models reported faster healing. The phrase describes a hoped-for effect, not an established one in people. Our article on tissue signalling peptides looks at how the term outran the evidence.

How does BPC-157 differ from TB-500?

They are unrelated peptides with different sequences and different research histories. See BPC-157 vs TB-500.

How much does BPC-157 cost in the UK?

Prices vary by supplier. At the time of writing, Thistle sells BPC-157 10mg at £27.99. Price says nothing about content or purity, so check the batch report whichever supplier you use.

Sources

• Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495. 36 studies; 35 preclinical, 1 retrospective; no clinical safety data.
• Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals. 2025;18(2):185.
• Sikiric P, Seiwerth S, Skrtic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions (comment on Józwiak et al.) and Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. Pharmaceuticals. 2025;18(10):1450 and 1451. Both published 28 September 2025. The angiogenesis and safety exchange; the reply gives the PubMed count and authorship figures.
• Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8–13. Retrospective, single centre; 17 treated, 16 followed up, 12 given BPC-157 alone.
• Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024. Open-label, 12 women.
• Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20–24. Two healthy adults.
• Sikiric P, Seiwerth S, Rucman R, et al. Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. Current Medicinal Chemistry. 2012;19(1):126–132. Sequence, molecular weight and the PL 14736 phase 2 programme.
• Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976–983. Primary rat study.
• Duzel A, Vlainic J, Antunovic M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. World Journal of Gastroenterology. 2017;23(48):8465–8488. Zagreb group; primary rat study.
• ClinicalTrials.gov. NCT02637284: Phase I pilot study of PCO-02 (BPC-157) in healthy volunteers. Sponsor PharmaCotherapia; 42 volunteers; status unknown; no results posted.
• US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page updated 22 April 2026; BPC-157 entry and the stated immunogenicity and impurity concerns. See also July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee; vote reported by Steinzor P, FDA Panel Backs 6 Peptides for Compounding. AJMC. 31 July 2026.
• Pharmacy Times. Heal or Harm? Body Protective Compound-157 in the Gray Zone. 1 July 2026.
• World Anti-Doping Agency. Prohibited List 2026. In force 1 January 2026; BPC-157 named as an example under S0 non-approved substances. First named on the 2022 list (UK Anti-Doping summary).
• Aesthetics Journal. MHRA investigates clinics following peptide claims. 15 April 2026.

Published by Thistle BioLabs, a UK supplier of research materials. This article summarises external research, not studies conducted by Thistle. Educational information only; no medical advice or recommendation for personal use.